Management Board ǀ Apogenix
By A Mystery Man Writer
Description
Apogenix develops innovative protein therapeutics for the treatment of cancer and other malignant diseases. Our lead drug candidate APG101 has demonstrated a statistically significant efficacy in a controlled phase II trial in recurrent glioblastoma.
Gene expression profiles in genome instability-based classes of colorectal cancer, BMC Cancer
Gene expression profiles in genome instability-based classes of colorectal cancer, BMC Cancer
Apogenix - Org Chart, Teams, Culture & Jobs
HERA Technology Platform ǀ Apogenix
Apogee Change Enablement Solutions
Regulatory chromatin rewiring promotes metabolic switching during adaptation to oncogenic receptor tyrosine kinase inhibition
Clinical Candidates ǀ Apogenix
Clinical Candidates ǀ Apogenix
Apogenix ǀ Immuno-oncology therapeutics for the treatment of cancer and other malignant diseases
from
per adult (price varies by group size)